Danaher/Abcam deal set to close next month; Cereno's loan; March Biosciences to advance its CAR-T into PhII
17 Nov 2023
Acquisition
Danaher’s proposed acquisition of Abcam is expected to close Dec. 6:
The companies
announced
the closing date on Friday. Danaher is paying $24 a share in cash. Jonathan Milner, Abcam’s founder and largest shareholder, had
campaigned against the deal
until earlier this month.
Cereno Scientific’s loan:
The Swedish biopharma developing cardiovascular treatments
said
Friday it received a loan for SEK 90 million, about $8.5 million. Formue Nord Fokus issued the loan, which is divided into two tranches, at a set-up fee of 5%. “We have secured optimal conditions to be able to maintain a strong position in discussions and potential negotiations with partners over an extended period,” Cereno CEO Sten Sörensen said in a release.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.